Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.31 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.31 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.31 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.31 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10129066 | 0.95 | TSHR (0.38) | TSHRHRH3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6602752 | 0.92 | TSHR (0.35) | TSHRHRH3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL24837667 | 0.92 | TSHR (0.39) | TSHRHRH3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL12717161 | 0.90 | TSHR (0.36) | TSHRHRH3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL22969999 | 0.87 | TSHR (0.32) | TSHRSLC6A2SLC6A4SLC6A3 | |
| Ammonia Solution, Strong SCHEMBL28870908 | 0.87 | TSHR (0.35) | TSHRHRH3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL29120904 | 0.83 | TSHR (0.33) | TSHRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL31637066 | 0.82 | TSHR (0.34) | TSHRHRH3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL10058645 | 0.79 | TSHR (0.36) | TSHRHRH3CARM1PRMT6PRMT8 | |
| SCHEMBL9690498 | 0.78 | RAD52 (0.38) | SLC6A2SLC6A4SLC6A3CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230082430-A1 | TRICYCLIC DEGRADERS OF IKAROS AND AIOLOS | C4 THERAPEUTICS, INC. (US) | 2023-03-16 | — | — | US | disclosed |
| US-11407732-B1 | Tricyclic degraders of Ikaros and Aiolos | C4 THERAPEUTICS, INC. (US) | 2022-08-09 | — | — | US | disclosed |
| US-11319312-B2 | Pharmaceutical compounds | HEPTARES THERAPEUTICS LIMITED | 2022-05-03 | — | — | US | disclosed |
| US-20210101893-A1 | PHARMACEUTICAL COMPOUNDS | NXERA PHARMA UK LIMITED (GB) | 2021-04-08 | — | — | US | disclosed |
| US-10858352-B2 | Pharmaceutical compounds | HEPTARES THERAPEUTICS LIMITED (GB) | 2020-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11319312-B2 | Pharmaceutical compounds | CHRM1, CHRM2, CHRM4 | TSHR 137/4885HRH3 46/4885SLC6A2 1436/4885 |
| US-11407732-B1 | Tricyclic degraders of Ikaros and Aiolos | CRBN, IKZF1, IKZF3 | TSHR 3284/4885HRH3 4201/4885SLC6A2 4825/4885 |
| US-20230082430-A1 | TRICYCLIC DEGRADERS OF IKAROS AND AIOLOS | CRBN, IKZF1, IKZF3 | TSHR 3284/4885HRH3 4201/4885SLC6A2 4825/4885 |
| US-10858352-B2 | Pharmaceutical compounds | CHRM1, CHRM2, CHRM4 | TSHR 137/4885HRH3 46/4885SLC6A2 1436/4885 |
| US-20210101893-A1 | PHARMACEUTICAL COMPOUNDS | CHRM1, CHRM2, CHRM4 | TSHR 137/4885HRH3 46/4885SLC6A2 1436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.